Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey

  • P. Schuetz
  • M. Batschwaroff
  • F. Dusemund
  • W. Albrich
  • U. Bürgi
  • M. Maurer
  • M. Brutsche
  • A. R. Huber
  • B. Müller
Article

Abstract

All published evidence on procalcitonin (PCT)-guided antibiotic therapy was obtained in trials where physicians knew that they were being monitored, possibly resulting in higher adherence to the PCT algorithm. This study investigates the effectiveness of PCT guidance in an observational quality control survey. We monitored antibiotic therapy and algorithm adherence in consecutive patients with respiratory tract infections admitted to the Kantonsspital Aarau, Switzerland, between May 2008 and February 2009. The results were compared to the site-specific results of the former ProHOSP study. Overall and more pronounced for patients with community-acquired pneumonia, the median duration of antibiotic treatment in this survey was shorter than the ProHOSP control patients (6 vs. 7 days, P = 0.048 and 7 vs. 9 days, P < 0.001). In 72.5% of patients, antibiotics were administered according to the prespecified PCT algorithm. No significant differences concerning adverse medical outcome could be detected. This study mirrors the use of PCT-guided antibiotic therapy in clinical practice, outside of trial conditions. If algorithm adherence is reinforced, antibiotic exposure can be markedly reduced with subsequent reduction of antibiotic-associated side effects and antibiotic resistance. The integration of the PCT algorithm into daily practice requires ongoing reinforcement and involves a learning process of the prescribing physicians.

References

  1. 1.
    Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131(1):9–19CrossRefPubMedGoogle Scholar
  2. 2.
    Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B (2007) Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 7:102CrossRefPubMedGoogle Scholar
  3. 3.
    Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174(1):84–93CrossRefPubMedGoogle Scholar
  4. 4.
    Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409):600–607CrossRefPubMedGoogle Scholar
  5. 5.
    Briel M, Schuetz P, Müller B, Young J, Schild U, Nusbaumer C, Périat P, Bucher HC, Christ-Crain M (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007CrossRefGoogle Scholar
  6. 6.
    Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177(5):498–505CrossRefPubMedGoogle Scholar
  7. 7.
    Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum CA, Schild U, Regez K, Schönenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302(10):1059–1066CrossRefPubMedGoogle Scholar
  8. 8.
    Schuetz P, Christ-Crain M, Müller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections—hope for hype? Swiss Med Wkly 139(23–24):318–326PubMedGoogle Scholar
  9. 9.
    Lee RW, Lindstrom ST (2007) A teaching hospital’s experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology 12(5):754–758CrossRefPubMedGoogle Scholar
  10. 10.
    Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336(4):243–250CrossRefPubMedGoogle Scholar
  11. 11.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543–551CrossRefPubMedGoogle Scholar
  12. 12.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717CrossRefPubMedGoogle Scholar
  13. 13.
    Calverley PM, Walker P (2003) Chronic obstructive pulmonary disease. Lancet 362(9389):1053–1061CrossRefPubMedGoogle Scholar
  14. 14.
    Gonzales R, Sande MA (2000) Uncomplicated acute bronchitis. Ann Intern Med 133(12):981–991PubMedGoogle Scholar
  15. 15.
    Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163(7):1730–1754PubMedGoogle Scholar
  16. 16.
    Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26(6):1138–1180CrossRefPubMedGoogle Scholar
  17. 17.
    Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106(2):196–204PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • P. Schuetz
    • 1
    • 2
  • M. Batschwaroff
    • 2
  • F. Dusemund
    • 2
  • W. Albrich
    • 2
  • U. Bürgi
    • 2
  • M. Maurer
    • 2
  • M. Brutsche
    • 2
  • A. R. Huber
    • 3
  • B. Müller
    • 2
  1. 1.Division of Internal MedicineUniversity Hospital BaselBaselSwitzerland
  2. 2.Department of Internal Medicine and Division of PulmologyKantonsspital AarauAarauSwitzerland
  3. 3.Department of Laboratory MedicineKantonsspital AarauAarauSwitzerland

Personalised recommendations